Latest Conference Articles

November 9th 2015, 2:22pm

PER® New York Lung Cancer Symposium

Multiple options currently exist for patients with EGFR-positive non–small cell lung cancer, with additional therapies on the horizon, making upfront treatment selection an increasingly difficult endeavor.

November 9th 2015, 12:50pm

PER® New York Lung Cancer Symposium

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

November 7th 2015, 4:47pm

LUGPA Annual Meeting

Philip J. Buffington, MD, chief medical officer at The Urology Group, discusses administering degarelix (Firmagon) and determining which patients to treat with the hormonal therapy.buffington-thumb.jpg

November 7th 2015, 1:27pm

PER® New York Lung Cancer Symposium

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

November 7th 2015, 1:07pm

PER® New York Lung Cancer Symposium

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.

November 7th 2015, 12:24pm

PER® New York Lung Cancer Symposium

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer and mesothelioma, which are two aggressive thoracic malignancies with few options.

November 7th 2015, 11:59am

PER® New York Lung Cancer Symposium

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

November 7th 2015, 10:36am

PER® New York Lung Cancer Symposium

Dr. Renato G. Martins talks about the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti CTLA-4, in the treatment of lung cancer.

November 7th 2015, 10:11am

LUGPA Annual Meeting

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

November 7th 2015, 9:59am

LUGPA Annual Meeting

The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.

November 6th 2015, 4:19pm

LUGPA Annual Meeting

Deepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association's (LUGPA's) chairman of health policy, discusses LUGPA's legislative advocacy efforts.

November 6th 2015, 3:54pm

LUGPA Annual Meeting

Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.

November 6th 2015, 2:32pm

LUGPA Annual Meeting

Raoul S. Concepcion, MD, FACS, director of Advanced Therapeutics at Urology Associates, PC, discusses healthcare's movement away from fee-for-service reimbursements.

November 6th 2015, 1:51pm

LUGPA Annual Meeting

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

November 6th 2015, 1:44pm

PER® Chemotherapy Foundation Symposium (CFS)

Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone for patients with BRAF-mutated metastatic melanoma.

November 6th 2015, 12:55pm

LUGPA Annual Meeting

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.

November 6th 2015, 12:19pm

PER® Chemotherapy Foundation Symposium (CFS)

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

November 6th 2015, 10:43am

PER® Chemotherapy Foundation Symposium (CFS)

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer.

November 6th 2015, 6:33am

PER® Chemotherapy Foundation Symposium (CFS)

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

November 6th 2015, 6:06am

LUGPA Annual Meeting

Evan R. Goldfischer, MD, MBA, FACS, director of the Research Department at Premier Medical Group of the Hudson Valley, discusses the benefits of integrated medical groups.